Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Yucai Wang"'
Autor:
Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier L. Munoz, Saurabh Dahiya, Amer M. Beitinjaneh, Miriam T. Jacobs, Joseph P. Mcguirk, Julie M. Vose, Andre Goy, Charalambos Andreadis, Brian T. Hill, Kathleen A. Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael L. Wang, Michael D. Jain
Publikováno v:
Journal of Clinical Oncology. 41:2594-2606
PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II
Autor:
Darragh F. O'Donoghue, Huong L. Truong, Heidi D. Finnes, Jennifer S. McDonald, Heather P. May, Stephen M. Ansell, N. Nora Bennani, Thomas M. Habermann, David J. Inwards, Patrick B. Johnston, Arushi Khurana, Yi Lin, Ivana N. Micallef, Grzegorz S. Nowakowski, Jonas Paludo, Luis F. Porrata, Gita Thanarajasingam, Carrie A. Thompson, Jose C. Villasboas, Yucai Wang, Thomas E. Witzig, Nelson Leung
Publikováno v:
JCO Oncology Practice. 18:e1908-e1917
PURPOSE: High-dose methotrexate (HDMTX; > 500 mg/m2) is an important component of lymphoma therapy. Serum MTX monitoring at 48 hours is the standard approach to identify those at increased risk of developing MTX toxicity. Our aim was to characterize
Autor:
Michael L. Wang, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, James N. Gerson, Ian Flinn, Benoit Tessoulin, Alvaro J. Alencar, Shuo Ma, David Lewis, Ewa Lech-Maranda, Joanna Rhodes, Krish Patel, Kami Maddocks, Nicole Lamanna, Yucai Wang, Constantine S. Tam, Talha Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Timothy S. Fenske, John F. Seymour, Andrew D. Zelenetz, Binoj Nair, Donald E. Tsai, Minna Balbas, Richard A. Walgren, Paolo Abada, Chunxiao Wang, Junjie Zhao, Anthony R. Mato, Nirav N. Shah
Publikováno v:
Journal of Clinical Oncology.
PURPOSE Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent (c) BTKi pre-treated mantle cell lymphoma (MCL), a population
Autor:
Carla Casulo, Melissa C. Larson, Jonathan R Day, Thomas Matthew Habermann, Izidore S. Lossos, Yucai Wang, Loretta J. Nastoupil, Christopher Strouse, Dai Chihara, Peter Martin, Jonathon Brett Cohen, Brad S. Kahl, Jia Ruan, Walter Richard Burack, Jean Louise Koff, Jonathan W. Friedberg, James Robert Cerhan, Christopher Flowers, Brian K. Link, Matthew J. Maurer
Publikováno v:
Journal of Clinical Oncology. 40:7573-7573
7573 Background: While most patients (pts) with follicular lymphoma (FL) usually have favorable outcomes, those with refractory disease after first-line anti-CD20 based immunochemotherapy (IC), or progression within 24 months of diagnosis (POD24) hav
Autor:
Luis F. Porrata, Gita Thanarajasingam, Thomas M. Habermann, Jose C. Villasboas, David J. Inwards, N. Nora Bennani, Yi Lin, Nicole McLaughlin, Patrick B. Johnston, Grzegorz S. Nowakowski, Carrie A. Thompson, Thomas E. Witzig, Ivana N. Micallef, Jonas Paludo, Yucai Wang, Stephen M. Ansell
Publikováno v:
Journal of Clinical Oncology. 39:e19527-e19527
e19527 Background: While extra nodal involvement by MCL is relatively common, involvement of the central nervous system (CNS) is a rare ( < 5% of cases) complication with limited treatment options. We report the outcomes of a large cohort of patients
Autor:
Raphael Mwangi, Rebecca L. King, A.L. Feldman, Carrie A. Thompson, Umar Farooq, Yucai Wang, Thomas E. Witzig, Thomas M. Habermann, James R. Cerhan, Matthew J. Maurer, Eric Mou, Sanjal Desai, Grzegorz S. Nowakowski
Publikováno v:
Journal of Clinical Oncology. 39:e13569-e13569
e13569 Background: Progress in understanding the molecular biology of DLBCL has led to development of complex molecular classifications that rely on sequencing methods. These molecular clusters are defined by activation of distinct pathways and may a
Autor:
Yi Lin, Yucai Wang, Jonas Paludo, Antoine N. Saliba, Carrie A. Thompson, Thomas E. Witzig, Xavier Andrade-Gonzalez, Luis F. Porrata, Harry E Fuentes, Gita Thanarajasingam, N. Nora Bennani, Jose C. Villasboas, Ivana N. Micallef, Zhuoer Xie, Thomas M. Habermann, David J. Inwards, Stephen M. Ansell, Patrick B. Johnston, Grzegorz S. Nowakowski
Publikováno v:
Journal of Clinical Oncology. 39:7542-7542
7542 Background: 60-70% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) can be cured with R-CHOP or R-CHOP-like immunochemotherapy. However, patients ≥80 years of age were either excluded or underrepresented in modern DLBCL t
Autor:
Ivana N. Micallef, Allison C. Rosenthal, Carrie A. Thompson, Thomas E. Witzig, Yucai Wang, Patrick B. Johnston, Seth M. Maliske, Mohamed A. Kharfan-Dabaja, James R. Cerhan, Luis F. Porrata, Thomas M. Habermann, David J. Inwards, Brian K. Link, Stephen M. Ansell, Jacob J. Orme, Matthew J. Maurer, Grzegorz S. Nowakowski, Umar Farooq, Aung M. Tun
Publikováno v:
Journal of Clinical Oncology. 39:7522-7522
7522 Background: Patients with newly diagnoseddiffuse large B-cell lymphoma (DLBCL) who achieve event-free survival at 24 months (EFS24) following immunochemotherapy (IC) have excellent overall survival (OS) similar to that of age- and sex-matched ge
Autor:
Carrie A. Thompson, Jonas Paludo, Jose C. Villasboas, Jithma P. Abeykoon, Xavier Andrade-Gonzalez, Yucai Wang, Antoine N. Saliba, Paul J. Hampel, N. Nora Bennani, Allison M. Bock, Zhuoer Xie, Evandro D. Bezerra, Harry E Fuentes, Gita Thanarajasingam, Caleb Scheckel
Publikováno v:
Journal of Clinical Oncology. 39:6539-6539
6539 Background: The impact of insurance status on survival in diffuse large B‐cell lymphoma (DLBCL), the most common aggressive lymphoma, has not been evaluated after the implementation of the Affordable Care Act (ACA). The aim of this study is to
Characteristics, outcomes, and risk factors of ICANS after axicabtagene ciloleucel: Does age matter?
Autor:
Arushi Khurana, Jonas Paludo, Matthew A. Hathcock, Yucai Wang, Radhika Bansal, Michael W. Ruff, Sherri A. Braksick, Stephen M. Ansell, Jose C. Villasboas, Yi Lin, Patrick B. Johnston, N. Nora Bennani, Kitsada Wudhikarn, Ivan D. Carabenciov
Publikováno v:
Journal of Clinical Oncology. 39:e19556-e19556
e19556 Background: CD19 chimeric antigen receptor T cell therapy possesses unique side effects including cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS). Age is a major risk factor for ICANS. However